Sugi Predict

Sugi Predict / Compounds / SCHEMBL1795673

SCHEMBL1795673

SCHEMBL1795673

O=C1c2ccccc2-c2ccc(I)cc21

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 3/20 0.55
▸ KMT2A Q03164 3/20 0.55
▸ CDC25B P30305 1/20 0.55
▸ NPC1 O15118 6/20 0.54
▸ RAB9A P51151 6/20 0.54
▸ SMN1; SMN2 Q16637 5/20 0.54
▸ ALDH1A1 P00352 5/20 0.54
▸ MAPK1 P28482 5/20 0.54
▸ TP53 P04637 2/20 0.54
▸ CYP3A4 P08684 2/20 0.54
▸ ELANE P08246 1/20 0.54
▸ TSHR P16473 1/20 0.54
▸ TDP1 Q9NUW8 1/20 0.54
▸ PTPRC P08575 7/20 0.52
▸ S100A4 P26447 4/20 0.52
▸ LMNA P02545 4/20 0.52
▸ PLA2G1B P04054 3/20 0.52
▸ ATG4B Q9Y4P1 3/20 0.52
▸ APAF1 O14727 2/20 0.52
▸ TDP2 O95551 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6449287 0.98 MEN1 (0.57) MEN1KMT2ACDC25BNPC1RAB9A
SCHEMBL14838621 0.95 MEN1 (0.55) MEN1KMT2ACDC25BNPC1RAB9A
SCHEMBL745377 0.95 PTPRC (0.59) MEN1KMT2ACDC25BNPC1RAB9A
SCHEMBL16267346 0.91 MAOA (0.50) MEN1KMT2ACDC25BNPC1RAB9A
SCHEMBL1795929 0.91 TGM2 (0.50) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL21224167 0.85 TGM2 (0.50) MEN1KMT2ACDC25BNPC1RAB9A
SCHEMBL1963896 0.85 S100A4 (0.50) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL25227687 0.83 PTPRC (0.39) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL27896043 0.83 PTPRC (0.39) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL1794418 0.78 S100A4 (0.68) MAPK1TDP1PTPRCS100A4CES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220315895-A1 METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS IMMUNEBRIDGE LLC 2022-10-06 — — US disclosed
CN-114127638-A Negative photosensitive resin composition, cured film, organic EL display, and method for producing cured film 东丽株式会社 2022-03-01 — — CN disclosed
US-20200255371-A1 COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE IMMUNEBRIDGE LLC 2020-08-13 — — US disclosed
US-7951791-B2 e.g. 2,7-bis-[(3R)-1-azabicyclo[2.2.2]octan-3-yloxy]-fluoren-9-one; alpha 7 Nicotinic acetylcholine receptors ligands; cognitive disorder, neurodegeneration, and neurodevelopmental disorders ABBOTT LABORATORIES (US) 2011-05-31 — — US disclosed
CN-102060947-A Dimeric fluorene grafted polystyrene UNIV SHENYANG 2011-05-18 — — CN disclosed
EP-2258682-A2 Amino-substituted tricyclic derivatives and methods of use Abbott Laboratories (US) 2010-12-08 — — EP disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 — — US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 — — US disclosed
US-7625932-B2 Pyrrole and pyrazole derivatives as potentiators of glutamate receptors ELI LILLY AND COMPANY (US) 2009-12-01 — — US disclosed
EP-1670757-B1 PYRROLE AND PYRAZOLE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS LILLY CO ELI (US) 2009-05-06 — — EP disclosed
CN-1237183-A 6-0-substituted ketolides with antibacterial activity ABBOTT CO (US) 1999-12-01 — — CN disclosed
EP-0929563-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY Abbott Laboratories (US) 1999-07-21 — — EP disclosed
US-5866549-A MACROLIDE ANTIBIOTICS ABBOTT LABORATORIES (US) 1999-02-02 — — US disclosed
WO-1998009978-A1 6-O-SUBSTITUTED KETOLIDES HAVING ANTIBACTERIAL ACTIVITY ABBOTT LABORATORIES (US) 1998-03-12 — — WO disclosed
EP-0092385-B1 HYDANTOIN DERIVATIVES FOR USE IN INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOREN COMPOUNDS ALCON LABORATORIES, INC. (US) 1991-06-12 — — EP disclosed
US-4820800-A Arylene sulfide polymers PHILLIPS PETROLEUM COMPANY (US) 1989-04-11 — — US disclosed
US-4540700-A Treatment of diabetic complications with certain spiro-imidazolidine-diones ALCON LABORATORIES, INC. (US) 1985-09-10 — — US disclosed
US-4436745-A TETRACYCLIC SPIROHYDANTOINS ALCON LABORATORIES, INC. (US) 1984-03-13 — — US disclosed
WO-1983003543-A1 METHOD OF INHIBITING ALDOSE REDUCTASE ACTIVITY, COMPOSITIONS THEREFOR AND PROCESS FOR PREPARING SPIRO-FLUOROFLUOREN AND SPIRO-DIFLUOROFLUOREN COMPOUNDS ALCON LAB INC (US) 1983-10-27 — — WO disclosed
EP-0092385-A2 Hydantoin derivatives for use in inhibiting aldose reductase activity, compositions therefor and process for preparing spiro-fluoren compounds ALCON LABORATORIES, INC. (US) 1983-10-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255371-A1 COMPOSITIONS AND METHODS OF MAKING EXPANDED HEMATOPOIETIC STEM CELLS USING DERIVATIVES OF FLUORENE FLI1, MCL1, HCLS1 MEN1 1060/4885KMT2A 1526/4885CDC25B 1488/4885
US-20220315895-A1 METHODS OF MAKING OLIGOPOTENT AND UNIPOTENT PRECURSORS MCL1, CD14, ICOS MEN1 864/4885KMT2A 1707/4885CDC25B 277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.